This means that many pro-apoptotic cancer therapies developed for malignancies (e.g., BCL-2 inhibitors) often possess inherent senolytic activity, making them immediately relevant for clearing pathogenic SnCs in aging tissues [35,36,37]. The gene discussed is BCL2; the disease is cancer.